PAGB welcomes reclassification of Nuromol

Published on: 19 August 2021


Following the decision by the Medicines and Healthcare products Regulatory Agency (MHRA) to allow the non-pharmacy sale of Nuromol Dual Action Pain Relief – a combination of paracetamol and ibuprofen – Michelle Riddalls, CEO of PAGB, the consumer healthcare association, said: “We fully supported the application to reclassify Nuromol from P (pharmacy-only) to GSL (general sales list) status and we welcome the MHRA’s announcement.

“Nuromol Dual Action Pain Relief contains two ingredients with a proven safety and efficacy record. It has been available in pharmacies in the UK for six years and meets all of the criteria for a switch allowing sales via general retail outlets.

“This product is a second line of treatment when paracetamol or ibuprofen alone have not provided relief for mild to moderate pain.

“Making it available outside pharmacies, and therefore for extended hours and in more locations, will broaden the options for people experiencing this kind of pain.

“Reclassifying medicines in this way is an important factor in enabling more people to take greater control over their own health by encouraging and supporting appropriate self care.

“It also helps to protect NHS resources such as GP appointments for those who need them most.”


PAGB welcomes reclassification of Nuromol